Experimental evidence suggest that FFAR-targeted therapies offer the potential to reduce hyperglycemia without inducing hypoglycemia, promote insulin sensitivity, reduce obesity, and prevent hepatic lipotoxicity. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.